AstraZeneca's (NYSE:AZN) share price is 18.0% higher in the past 12 months and has outperformed the overall US TECH market which is 3.9% higher in the same timeframe. This means a 14.1% greater return over the period which puts the share price as an outperformer vs other US TECH companies.
From 5 analysts that cover AstraZeneca's stock, the average rating is 4.4. This is a weighted average of 3 strong buys, 1 buys, 1 holds. This is 0.0 lower than a month ago which gives this factor a tea-score of 3/5.
AstraZeneca insider's have net been buying stock over the past 12 months, in the previous month insiders have been net buying. In fact the buy to sell ratio in the past month has been 50.0% which is 50.0% lower than the last 12 months buy to sell ratio. This put's AstraZeneca's Insiders in the top quintile vs their peers giving this factor a tea-score of 3/5.
For AstraZeneca, currently 19.4% of stock (1 billion shares) is owned by Institutions, 80.6% (802 million shares) is owned by Individuals, and 0.0% (2 million shares) is owned by company insiders. The CEO has a holding of 0.02% which is equivalent to 40 thousand shares with a market value of $129 million. This factor has a tea-score of 5/5.
As of 31 July 2019, the short interest for AstraZeneca has been 0.55% of the shares outstanding which is 143 billion shares. This is more than 1 month ago which had 0.45% of the shares outstanding which is 118 billion short interest in shares. This equals a tea-score of 5/5.
AstraZeneca's revenue in the last 12 months ending 30 June 2019 is $23Bn. AstraZeneca's average revenue growth for the last 4 years has been 5.1% which is currently lower than their comps of 6.2%.
AstraZeneca's free cash flow yield is 1.6% and has shrunk from 4 years ago. The free cash flow yield for AstraZeneca 1 year ago was 2.6% and 3 years ago it was 2.6%.
AstraZeneca pays dividends every 5 months and has done so since 02 April 2013. Dividends have been steadily decreasing over the past 4 years from $0.45 (dividend yield of 1.57%) to $0.45 today (yield of 1.02%).
AstraZeneca's PE ratio is 51.8x. This is calculated from their EPS of $2.02 and price per share of $44.34. AstraZeneca's PE ratio values the company cheaper than 100% of it's competitors giving this factor a tea-score of 5/5.
AstraZeneca's PEG ratio is nanx. This is calculated from their PE ratio of 51.8x and their last 12 months growth rate of -0.629%. This is less attractive than their competitors so the tea-score for this factor is nan/5.
The PB ratio for AstraZeneca is 8.6x. This is more expensive than their competitors who have an average PB ratio of 3.8x. The tea-score is 5/5.
AstraZeneca's free cash flow yield is 1.6% which is ranked 2.0/5 when compared to its competitors. This is calculated from a free cash flow of $1Bn (as reported for the 12 months ending 30 June 2019) divided by its current market capitalisation of $114Bn. The average free cash flow yield across AstraZeneca's comps is 8.1%.
AstraZeneca's return on investment is 14.2%. This is more profitable than its competitors.
AstraZeneca's current ratio is calculated by (current assets) / (current liabilities) which equals 0.9x. This less attractive than their competitors and also worse than recommended for a healthy company.
AstraZeneca's debt to shareholder equity is 144.5%. This is worse than their competitors and also worse than advised for a well-managed balance sheet.
AstraZeneca's dividend payout ratio calculated against their free cash flow is low at 134.4%. This is in quintile 2 when measured against their comps.
AstraZeneca's has a poor overall ESG rating of nan/100. Their competitors have a score between nan and nan with the average at nan.
What is the 52 week high for AstraZeneca stock quote?
AstraZeneca (NYSE:AZN) hit a new 52-week high on 13 August 2019 at a price of $44.86 with 3,457,500 shares traded that day. This is 1.2% higher than than its current price of $44.34 and 29.3% higher than the 52-week low of $34.69 on 28 January 2019. Average daily volume traded has been 2 million shares over the past 3 months.
What is the highest price AstraZeneca stock has ever been?
The all-time highs for AstraZeneca stock were reached on 13 August 2019, 6 days ago at a price of $44.86. This equates to a market capitalisation of $117Bn. The highest price reached is 1.2% higher than the current price of $44.34 with a current market cap of $114Bn.
What is the beta of AstraZeneca stock?
AstraZeneca stock moves 0.5x the US TECH market average which makes its beta higher than the overall market.
What is the volatility of AstraZeneca (AZN) stock?
AstraZeneca's stock has an annual volatility of 22.8% which is more volatile than the average US TECH market volatility of 16.3% which has made it a less safe stock to own in the past vs just owning the index for investors aiming for lower portfolio volatility.
What have AstraZeneca's share buybacks been over the past year?
AstraZeneca is currently running a share-buyback program and in the past year alone the company has repurchased 104 million of shares outstanding at a total expense of $23Trn. In the same time frame the share price has moved 18.0% higher which is an outperformance of 14.1% vs the overall market. AstraZeneca still has $420Trn of cash remaining on their balance sheet.
Who owns the most AstraZeneca stock?
Barry White is the largest individual shareholder in AstraZeneca with 1 billion shares. He is an independent director of AstraZeneca. The largest institutional holder is T-Rowe and they own 3.8% of the issue size with 100 million shares. T-Rowe have been net buying shares over the last 12 months as they own 1 million more shares than a year ago.
When did AstraZeneca beat earnings expectations in the last 4 years?
In the past 4 quarters AstraZeneca has had 3 earnings beat's and 1 earnings miss's. The average earnings beat has been 12.1% and the average earnings miss has been 8.2%.
When is AstraZeneca's next earnings date and what are the expectations?
AstraZeneca is set to report earnings on 30 July 2019 after market close. The report will be for the fiscal Quarter ending June 2019. Based on 14 analysts' forecasts, the consensus EPS forecast for the quarter is $2.12. Recent analyst revisions have been positive implying a potential EPS of $2.24.
What is AstraZeneca's upcoming earnings report expectations?
The earnings expectations for AstraZeneca's upcoming report on 30 July 2019 are from 14 analysts with an average EPS of $2.12. The lowest analyst rating is $2.01, the highest is $2.84. The most recent earnings revisions have been positive with a most recent estimate of $2.24.
What is AstraZeneca's earnings per share (EPS)?
AstraZeneca's latest earnings per share (EPS) was reported as $2.02 on 30 April 2019 for fiscal quarter ending March 2019. This is 11.0% higher than 12 months ago when they reported EPS of $1.82
What is AstraZeneca's dividend growth rate?
AstraZeneca's dividends have grown at 0.00% in the past year and an average growth of 0.00% over the past 4 years. This is lower then it's competitors 4-year average dividend growth of 4.1
What is AstraZeneca's dividend yield?
AstraZeneca's current dividend yield is 1.02%. This is calculated by taking the dividend's per share of $0.45 (the last payment which was on 08 August 2019) and dividing by the current share price of $44.34.
What is AstraZeneca's previous and next dividend date?
AstraZeneca's most recent dividend date was 08 August 2019 when the company paid $0.45 and the next dividend date is 16 January 2020 with an expected payment of $0.45.